If you are having trouble viewing this e-mail, please click here.
Lessons Learned with Steve Lam
For some companies, bioprocessing is a well-oiled machine. For others, it’s a car crash capable of derailing a product launch by months. Steve Lam argues establishing a manufacturing strategy early in development will pay dividends down the line.
If the UK remained within the single market after Brexit, it would retain access to pharmacovigilance databases and UK-based EEA-QPPVs could remain within the UK. And with the Article 50 clock ticking, will the UK government consider EEA/EFTA membership?
Researchers have created a new database of FDA-approved drug compounds that can be used to easily compare combinations of drugs. It’s called the Centre of Excellence for Medical Multimedia (CeMM) Library of Unique Drugs – CLOUD for short.
The Evolution of Bioprocessing: Is biopharma ready to embrace continuous solutions?
There is tremendous pressure to reduce the cost of developing new medicines, while at the same time maintaining high standards for quality and safety. It’s clear that changes are needed in the bio/pharma industry’s manufacturing models – and continuous processing may be the answer. In this collection of articles, experts from Pall Life Sciences explain why a growing number of companies are investigating the potential of continuous bioprocessing technologies, and why single use systems are key to making the switch.
Be it a large congress at a huge venue or an expert meeting that fits around a table, these events are a fantastic way to network and educate yourself on the latest developments in the industry – so why not take a look at our list of upcoming events?